Hospira Vincristine Sulphate 5 mg/5 mL Injection vial (preserved)

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

vincristine sulfate, Quantity: 1 mg/mL

Commercializzato da:

Hospira Australia Pty Ltd

INN (Nome Internazionale):

Vincristine sulfate

Forma farmaceutica:

Injection, solution

Composizione:

Excipient Ingredients: benzyl alcohol; mannitol; water for injections

Via di somministrazione:

Intravenous

Confezione:

5 x 5 mL pack

Classe:

Medicine Listed (Export Only)

Tipo di ricetta:

(S1) This Schedule is intentionally blank

Indicazioni terapeutiche:

Vincristine Sulphate Injection is used in the treatment of cancers of the blood (eg. leukaemia or lymphomas), breast, head and neck or lung. It may be used to treat multiple myeloma (a cancer of plasma cells) and it may also be used in the treatment of some cancers in children. It may be used in a blood disorder known as idiopathic thrombocytopenic purpura (ITP) after other treatments have not been successful. Vincristine Sulphate Injection may be given alone or in combination with other anti-cancer medicines.

Dettagli prodotto:

Visual Identification: A clear colourless solution; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 18 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2011-11-02